Tuesday, 29 April 2025
  
Login

Australia's most trusted
source of pharma news

Tuesday, 29 April 2025
News

Approval tainted by PBAC 'No'

Posted 28 April 2025 AM

Otsuka owned Taiho Pharma has secured the TGA’s provisional approval for its bile duct cancer treatment Lytgobi but will now need to resubmit the drug to PBAC.

The kinase inhibitor is indicated for the treatment of adults with locally advanced or metastatic intrahepatic cholangiocarcinoma with a FGFR2 fusion or rearrangement that have progressed after at least one prior line of systemic therapy.

To see the whole article, please login

Popular

Yes... but with a price reduction
Approval tainted by PBAC 'No'
Finally, a PBS listing after 1514 days
TGA hunting Committee experts
Latest Jobs
MORE NEWS
Email this article to a friend
From:

 
 
  
Print this article

Copyright Notice

Please click the button to indicate that the printout of this article is for your personal use only and not for any type of redistribution.

Redistribution of the whole or part of Pharma in Focus by any means is a breach of copyright law.

Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.


Subscribe
 
© 2003 - 2025 Lush Media | Privacy Statement | Subscribe to Pharma in Focus
home